Pharma & Biotech - Page 7

President Donald Trump signed an executive order on August 10, 2026, titled “Delivering Gold Standard Childhood Vaccine Recommendations for Americans,” narrowing the recommended childhood vaccine list. The order reduces the number of

The prolonged Strait of Hormuz standoff is deepening concerns across pharmaceutical supply chains, with no resolution appearing imminent from either side. President Trump has signalled the US is prepared to let economic

Tenax Therapeutics (Nasdaq: TENX) has announced that its Phase 3 LEVEL clinical trial evaluating TNX-103, an oral form of levosimendan, failed to meet its primary endpoint. The trial, which enrolled 241 patients

Bristol Myers Squibb (NYSE: BMY) has selected Houston, Texas, as the location for a new multi-modal manufacturing campus representing approximately $2.3 billion in investment. The facility will be built at Generation Park

Bristol Myers Squibb (NYSE: BMY) has announced plans to build a major new manufacturing campus in Houston, Texas, representing a $2.3 billion investment in domestic production capacity. The facility will be located

Health insurers and pharmacy benefit managers are growing increasingly cautious about how the TrumpRx drug pricing programme could reshape the prescription medication landscape for patients. The initiative introduces federal pricing benchmarks that

AstraZeneca and Bristol Myers Squibb have no ongoing discussions about a potential merger, according to a senior source close to the matter cited by Reuters. “There is no deal between AstraZeneca and

Gilead Sciences has reached a significant commercial milestone, with its HIV prevention franchise surpassing $1 billion in quarterly sales for the very first time. The breakthrough was driven by strong performance from

Novo Nordisk’s oral Wegovy treatment continues to post impressive results in 2026, sustaining momentum as the company eyes broader international expansion beyond the United States. Chief Executive Mike Doustdar struck a confident

Alcon (ALC) has released findings from a new survey highlighting a significant disconnect between parental awareness of vision health and actual eye examination rates among teenagers. The survey, conducted by Wakefield Research